Terms: = Head and neck cancer AND STAT3, FLJ20882, 6774, ENSG00000168610, APRF, P40763, MGC16063 AND Prognosis
164 results:
1. PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and stat3/HSP60 signaling pathways to treat nasopharyngeal carcinoma.
Cao J; Zeng K; Chen Q; Yang T; Lu F; Lin C; Zhan J; Ma W; Zhou T; Huang Y; Luo F; Zhao H
Cell Death Dis; 2024 Mar; 15(3):237. PubMed ID: 38555280
[TBL] [Abstract] [Full Text] [Related]
2. Unlocking the Therapeutic Potential of LncRNA
Liu FL; Zhang ZC; Zhou SL; Liu XL; Xu W
Discov Med; 2024 Mar; 36(182):546-558. PubMed ID: 38531795
[TBL] [Abstract] [Full Text] [Related]
3. Hypoxia-induced miR-5100 promotes exosome-mediated activation of cancer-associated fibroblasts and metastasis of head and neck squamous cell carcinoma.
Duan Y; Zhou M; Ye B; Yue K; Qiao F; Wang Y; Lai Q; Wu Y; Cao J; Wu Y; Wang X; Jing C
Cell Death Dis; 2024 Mar; 15(3):215. PubMed ID: 38485986
[TBL] [Abstract] [Full Text] [Related]
4. TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
Ma L; Qin N; Wan W; Song S; Hua S; Jiang C; Li N; Huang L; Gao X
Am J Physiol Cell Physiol; 2024 Feb; 326(2):C362-C381. PubMed ID: 38105756
[TBL] [Abstract] [Full Text] [Related]
5. Nasopharyngeal carcinoma with non-squamous phenotype may be a variant of nasopharyngeal squamous cell carcinoma after inhibition of EGFR/PI3K/AKT/mTOR pathway.
Wang J; Shang Y; Wang Y; Li Y; Wang L; Huang S; Lyu X
Histol Histopathol; 2024 May; 39(5):647-657. PubMed ID: 37971211
[TBL] [Abstract] [Full Text] [Related]
6. The role of microbiota in esophageal squamous cell carcinoma: A review of the literature.
Chiang HC; Hughes M; Chang WL
Thorac Cancer; 2023 Oct; 14(28):2821-2829. PubMed ID: 37675608
[TBL] [Abstract] [Full Text] [Related]
7. [Clinicopathological features of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma].
Zhu M; Li J; Zheng WH; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2023 Aug; 52(8):820-826. PubMed ID: 37527987
[No Abstract] [Full Text] [Related]
8. Molecular and biological factors in the prognosis of head and neck squamous cell cancer.
Naumov SS; Kulbakin DE; Krakhmal NV; Vtorushin SV
Mol Biol Rep; 2023 Sep; 50(9):7839-7849. PubMed ID: 37493876
[TBL] [Abstract] [Full Text] [Related]
9. Exosome-mediated long noncoding RNA (lncRNA) PART1 suppresses malignant progression of oral squamous cell carcinoma via miR-17-5p/SOCS6 axis.
Du Y; Shuai Y; Wang H; Li H; Li Y
Turk J Med Sci; 2023 Jun; 53(3):630-639. PubMed ID: 37476905
[TBL] [Abstract] [Full Text] [Related]
10. DACH1 regulates macrophage activation and tumour progression in hypopharyngeal squamous cell carcinoma.
Li W; Xu L; Cao J; Ge J; Liu X; Liu P; Teng Y; Wang S; Sun Y; Liu M; Tian L
Immunology; 2023 Oct; 170(2):253-269. PubMed ID: 37243970
[TBL] [Abstract] [Full Text] [Related]
11. Anti‑tumor properties of FoxO1 in YD‑9 oral squamous cell carcinoma cells.
Kim YG; Seong C; Cho KA; Lee SM; Kim TJ; Kim HJ; Cho JH; Jung W; Jang S; Shin JC; Lee KH; Byun JS; Kim DY
Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37144504
[TBL] [Abstract] [Full Text] [Related]
12. DUSP4 promotes esophageal squamous cell carcinoma progression by dephosphorylating HSP90β.
Zhou L; Yao N; Yang L; Liu K; Qiao Y; Huang C; Du R; Yeung YT; Liu W; Cheng D; Dong Z; Li X
Cell Rep; 2023 May; 42(5):112445. PubMed ID: 37141098
[TBL] [Abstract] [Full Text] [Related]
13. Radiotherapy opens the blood-brain barrier and synergizes with anlotinib in treating glioblastoma.
Li PJ; Lai SZ; Jin T; Ying HJ; Chen YM; Zhang P; Hang QQ; Deng H; Wang L; Feng JG; Chen XZ; Guo P; Chen M; Tian Y; Chen YY
Radiother Oncol; 2023 Jun; 183():109633. PubMed ID: 36963438
[TBL] [Abstract] [Full Text] [Related]
14. LncRNA MALAT1 promotes growth and metastasis of head and neck squamous cell carcinoma by repressing VHL through a non-canonical function of EZH2.
Duan Y; Yue K; Ye B; Chen P; Zhang J; He Q; Wu Y; Lai Q; Li H; Wu Y; Jing C; Wang X
Cell Death Dis; 2023 Feb; 14(2):149. PubMed ID: 36813772
[TBL] [Abstract] [Full Text] [Related]
15. Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models.
Su L; Chen Y; Huang C; Wu S; Wang X; Zhao X; Xu Q; Sun R; Kong X; Jiang X; Qiu X; Huang X; Wang M; Wong PP
Sci Transl Med; 2023 Jan; 15(678):eabl7895. PubMed ID: 36630483
[TBL] [Abstract] [Full Text] [Related]
16. ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells.
Gao Z; Xu J; Fan Y; Zhang Z; Wang H; Qian M; Zhang P; Deng L; Shen J; Xue H; Zhao R; Zhou T; Guo X; Li G
J Exp Clin Cancer Res; 2022 Nov; 41(1):323. PubMed ID: 36380368
[TBL] [Abstract] [Full Text] [Related]
17. ENO1 Binds to ApoC3 and Impairs the Proliferation of T Cells via IL-8/stat3 Pathway in OSCC.
Wang J; Man Q; Zhong N; Wang H; Zhang C; Li S; Bu L; Liu B
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361568
[TBL] [Abstract] [Full Text] [Related]
18. Investigation on the regulatory T cells signature and relevant Foxp3/stat3 axis in esophageal cancer.
Yang L; Zhao Q; Wang X; Pilapong C; Li Y; Zou J; Jin J; Rong J
Cancer Med; 2023 Feb; 12(4):4993-5008. PubMed ID: 36226375
[TBL] [Abstract] [Full Text] [Related]
19. Integrated analysis of novel macrophage related signature in anaplastic thyroid cancer.
Luo Y; Yang YC; Ma B; Xu WB; Liao T; Wang Y
Endocrine; 2022 Dec; 78(3):517-530. PubMed ID: 36070052
[TBL] [Abstract] [Full Text] [Related]
20. Identification of the alpha linolenic acid metabolism-related signature associated with prognosis and the immune microenvironment in nasopharyngeal carcinoma.
Fang Z; Huang H; Wang L; Lin Z
Front Endocrinol (Lausanne); 2022; 13():968984. PubMed ID: 35992141
[TBL] [Abstract] [Full Text] [Related]
[Next]
